O8-4 KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC

Kaoru Kubota,Byoung Chul Cho,Vichien Srimuninnimit,Yu Fan,Jianying Zhou,Li Zhang,Qing Zhou,Yukio Hosomi,Hiroaki Takeoka,Rinee Mukherjee,Wei Fu,Fabricio Souza,Tony S.K. Mok,Li Zhang

DOI: https://doi.org/10.1016/j.annonc.2022.05.032

IF: 51.769

2022-01-01

Annals of Oncology

Abstract:Five-year follow-up from KEYNOTE-042, a global phase 3 trial in patients (pts) with previously untreated, locally advanced/metastatic NSCLC with PD-L1 TPS ≥1% and no sensitizing EGFR/ALK alterations showed longer OS with pembrolizumab (pembro) vs chemotherapy (chemo) for PD-L1 TPS ≥50% (HR 0.68), ≥20% (HR 0.75), and ≥1% (HR 0.79). We report outcomes with about 5y follow-up in pts enrolled in Asia.